Therma Bright Receives Patent for Topical Treatment Application Device from US Patent and Trademark Office (USPTO)

Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its AcuVid™ COVID -19 Smart System Rapid Antigen Saliva Test and other advanced diagnostic and medical device technologies, is pleased to announce that on February 4, 2022, the United States Patent and Trademark Office has granted United States Patent Application (US 15/ 787,599) which covers an apparatus that can apply heat and antimicrobial treatment through a detachable applicator surface comprising copper or silver to provide thermal conductivity and a source of antimicrobial agent. The device also includes a light source. This US patent applies to both Therma Bright products InterceptCS™ cold sore prevention device and TherOZap™ Insect Bite Relief Device.

Specific to the InterceptCS™ device, this thermal and antimicrobial treatment technology is combined as the solution for the prevention of cold sores. As for the TherOZap™ device, the treatment technology aims to reduce the inflammatory response, relieving the symptoms of pain, itching and inflammation associated with insect bites and stings. Additionally, as noted in previous press releases, the Company has engaged a leading virology research laboratory in Canada to study the ability of TherOZap™ technology to inactivate live Zika virus in culture media and that the TherOZap™, which uses specialized materials, coatings and heat, was able to limit the replication of the Zika virus (“ZIKV”) in cell cultures.

“This is great news for Therma Bright and our TherOZap™ insect relief device and InterceptCS™ cold sore prevention device,” said Rob Fia, CEO of Therma Bright. “This authorized U.S. patent application further protects our valuable intellectual property (IP) as we continue to turn innovation into well-being.”

Therma Bright is currently undergoing design upgrades to both devices and expects to complete prototyping in Q2. Additionally, the Company plans to continue research with the new TherOZap™ design on Zika and other mosquito-borne diseases in 2022.

About Therma Bright Inc.
Therma Bright, developer of the smart AcuVid™ COVID-19 Rapid Antigenic Saliva Test, is a progressive diagnostic and medical device technology company focused on providing consumers and healthcare professionals with quality, innovative solutions that address some of today’s most important medical and healthcare challenges. The company’s revolutionary initial patented technology provides effective, non-invasive and painless skin care. Therma Bright has received Class II medical device status from the FDA for its platform technology indicated for the relief of pain, itching, and inflammation from a variety of stings or insect stings. The Company received US FDA clearance for the above claims in 1997. Therma Bright Inc. trades on the TSX Venture Exchange (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) . To visit:

For more information, please contact:
Therma Bright Inc.
Rob Fia, CEO
[email protected]

follow us on Twitter

Certain statements contained in this press release constitute “forward-looking” statements. These statements relate to future events such as the development and commercialization of a COVID-19 rapid viral test and associated instrumentation, regulatory applications, and manufacturing ramp-up, as described in the press release. All of these statements involve substantial known and unknown risks, uncertainties and other factors that may cause actual results to differ from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, should not be construed as guarantees of future performance or results, and will not necessarily be specific indications as to whether or not such results will be achieved. Actual results could differ materially from those anticipated due to a number of factors and risks. Although the forward-looking statements contained in this press release are based on what management of the Company considers to be reasonable assumptions as of the date of this press release, the Company cannot assure investors that actual results will be consistent with such statements. forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless necessary. under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release does not constitute an offer of securities for sale in the United States. The securities have not been registered under the US Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from registration. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of the securities in any state where such offer, solicitation or sale would be unlawful.

To view the source version of this press release, please visit

Comments are closed.